<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02843386</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2008-03</org_study_id>
    <nct_id>NCT02843386</nct_id>
  </id_info>
  <brief_title>Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma</brief_title>
  <acronym>FOTEADJ</acronym>
  <official_title>Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servier</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external&#xD;
      radiotherapy) patients with high risk of metastasis are randomized between:&#xD;
&#xD;
        -  Adjuvant chemotherapy with Fotemustin.&#xD;
&#xD;
        -  Observation&#xD;
&#xD;
      Both groups are followed during 3 years for Metastasis- Free Survival, safety and tolerance&#xD;
      of Fotemustin, quality of life, and Overall Survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High risk uveal melanoma is defined by :&#xD;
&#xD;
        -  Clinical criteria: Largest Tumor Diameter ≥ 15 mm with extra scleral extension and/or&#xD;
           retinal detachment or Largest Tumor Diameter ≥ 18 mm AND/ OR&#xD;
&#xD;
        -  Genomic high risk signature (aCGH +/-LOH): Monosomy 3 or partial deletion of 3p&#xD;
           associated with any 8 gain.&#xD;
&#xD;
      Treatment schedule :&#xD;
&#xD;
        -  Induction: Fotemustin 100 mg/m², D1-D8-D15, 1 hour IV infusion, 1 cycle&#xD;
&#xD;
        -  Maintenance : restart on D50, Fotemustine : 100 mg/m², 1 hour IV infusion, D1 D21, 5&#xD;
           cycles.&#xD;
&#xD;
      Both groups are followed during 3 years for Metastasis- Free Survival, safety and tolerance&#xD;
      of Fotemustin, quality of life, and Overall Survival.&#xD;
&#xD;
      Note :Based on the second interim analysis showing futility, and no chance to observe any&#xD;
      significant statistical difference at the end of the study, the Independent Data Monitoring&#xD;
      Committee recommended to stop randomization and amend the protocol to propose an&#xD;
      interventional surveillance to high-risk patients as per protocol (April 2016).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">June 23, 2009</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-Free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time between patient randomization and metastases occurrence or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time between patient randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : incidence of Adverse Events and Serious Adverse Events and laboratory abnormalities</measure>
    <time_frame>3 years</time_frame>
    <description>using National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) V3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Baseline, 6 months and 3 years</time_frame>
    <description>Using QLQ-C30 questionary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>A : Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjuvant chemotherapy by Fotemustin 100mg/m²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B : Surveillance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intensive surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy by Fotemustin</intervention_name>
    <description>Fotemustin is given for 6 cycles :&#xD;
One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.&#xD;
Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21.</description>
    <arm_group_label>A : Chemotherapy</arm_group_label>
    <other_name>Fotemustin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive surveillance</intervention_name>
    <description>Intensive surveillance&#xD;
Total duration: 3 years.&#xD;
liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months.</description>
    <arm_group_label>B : Surveillance</arm_group_label>
    <other_name>Surveillance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. High risk uveal melanoma, defined by :&#xD;
&#xD;
               -  Clinical criteria: Largest Tumor Diameter ≥ 15 mm with extrascleral extension&#xD;
                  and/or retinal detachment or Largest Tumor Diameter ≥ 18 mm AND/OR&#xD;
&#xD;
               -  Genomic high risk signature (cCGH +/- LOH) : Monosomy 3 or partial deletion of 3p&#xD;
                  and any 8 gain, from enucleation, transscleral or transvitreal samples&#xD;
&#xD;
          2. Age ≥ 18 years and ECOG Performance Status ≤ 2&#xD;
&#xD;
          3. No prior chemotherapy or history of invasive cancer &lt; 5years&#xD;
&#xD;
          4. No metastases&#xD;
&#xD;
          5. Local treatment for the primary tumour (surgery and/or radiotherapy) achieved ≤ 30&#xD;
             days from randomization, chemotherapy to begin within 15 days.&#xD;
&#xD;
        6 - Contraception in women of child-bearing potential&#xD;
&#xD;
        7- Written informed consent&#xD;
&#xD;
        8- Patients with French Social Security in compliance with the French law relating to&#xD;
        biomedical research.&#xD;
&#xD;
        Non-Inclusion Criteria:&#xD;
&#xD;
          1. Largest Tumor Diameter &lt; 15 mm or Largest Tumor Diameter 15-18 mm without extrascleral&#xD;
             extension and/or retinal detachment, in the absence of genomic alteration as defined&#xD;
             per protocol or in the absence of Fine Needle Aspiration biopsy for genomic risk&#xD;
             assessment.&#xD;
&#xD;
          2. Contraindication to Fotemustine administration&#xD;
&#xD;
          3. Hematological function : Hb &lt; 10g/dL, absolute neutrophil count &lt; 2,000/mm3, and&#xD;
             platelets &lt; 100,000/mm3&#xD;
&#xD;
          4. Biochemistry results :Total bilirubin and AST/ALT &gt; 1,5 UNL (Upper Normal Limit)&#xD;
&#xD;
          5. Creatinine &gt; 1,5 UNL (Upper Normal Limit)&#xD;
&#xD;
          6. Pregnant and/or breastfeeding women.&#xD;
&#xD;
        8 - Previous history of cancer excepting in situ cervical carcinoma or cutaneous basal&#xD;
        carcinoma.&#xD;
&#xD;
        7- Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
        infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
        arrhythmia, viral or other hepatitis or cirrhosis, or psychiatric illness/social situation&#xD;
        that would interfere with the protocol or limit compliance with study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveal melanoma</keyword>
  <keyword>High risk of metastasis</keyword>
  <keyword>Genomic high risk signature</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

